{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:58:09Z","timestamp":1772510289019,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T00:00:00Z","timestamp":1488153600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11899-017-0370-5","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T08:53:08Z","timestamp":1488185588000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["An Evidence-Based Approach to Myeloma Bone Disease"],"prefix":"10.1007","volume":"12","author":[{"given":"Nicholas","family":"Bingham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Reale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"key":"370_CR1","doi-asserted-by":"publisher","unstructured":"Anderson KC, Alsina M, Atanackovic D. Multiple Myeloma. J Natl Compr Canc Netw. 2016;13(11):1398\u20131435.","DOI":"10.6004\/jnccn.2015.0167"},{"key":"370_CR2","doi-asserted-by":"publisher","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","volume":"24","author":"P Moreau","year":"2013","unstructured":"Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi133\u20137. doi: 10.1093\/annonc\/mdt297 .","journal-title":"Ann Oncol"},{"key":"370_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","volume":"2","author":"R Silbermann","year":"2013","unstructured":"Silbermann R, Roodman GD. Myeloma bone disease: pathophysiology and management. J Bone Oncol. 2013;2:59\u201369. doi: 10.1016\/j.jbo.2013.04.001 .","journal-title":"J Bone Oncol"},{"key":"370_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4252\/wjsc.v6.i3.322","volume":"6","author":"A Garc\u00eda-G\u00f3mez","year":"2014","unstructured":"Garc\u00eda-G\u00f3mez A, Sanchez-Guijo F, del Canizo C. Multiple myeloma mesenchymal stromal cells: contribution to myeloma bone disease and therapeutics. WJSC. 2014;6:322. doi: 10.4252\/wjsc.v6.i3.322 .","journal-title":"WJSC"},{"key":"370_CR5","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3109\/10428194.2011.573036","volume":"52","author":"E Tan","year":"2011","unstructured":"Tan E, Weiss BM, Mena E, Korde N, Choyke PL, Landgren O. Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma. 2011;52:1630\u201340. doi: 10.3109\/10428194.2011.573036 .","journal-title":"Leuk Lymphoma"},{"key":"370_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254\u201366. doi: 10.3324\/haematol.2014.117176 .","journal-title":"Haematologica"},{"key":"370_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/104546","volume":"2013","author":"P Tosi","year":"2013","unstructured":"Tosi P. Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica. 2013;2013:1\u201312. doi: 10.1155\/2013\/104546 .","journal-title":"Scientifica"},{"key":"370_CR8","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","volume":"31","author":"E Terpos","year":"2013","unstructured":"Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, et al. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31:2347\u201357. doi: 10.1200\/JCO.2012.47.7901 .","journal-title":"J Clin Oncol"},{"key":"370_CR9","doi-asserted-by":"publisher","unstructured":"Hameed, Brady J, Dowling P, Clynes M, O\u2019Gorman P. Bone disease in multiple myeloma: pathophysiology and management. CGM. 2014:33\u201310. doi: 10.4137\/CGM.S16817","DOI":"10.4137\/CGM.S16817"},{"key":"370_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21\u201333. doi: 10.4065\/78.1.21 .","journal-title":"Mayo Clin Proc"},{"key":"370_CR11","unstructured":"Berenson JR, Porter L, Lichtenstein A. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med. 2000;334(8):1\u20136."},{"key":"370_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1359\/JBMR.041131","volume":"20","author":"LJ Melton III","year":"2004","unstructured":"Melton III LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2004;20:487\u201393. doi: 10.1359\/JBMR.041131 .","journal-title":"J Bone Miner Res"},{"key":"370_CR13","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisl\u00f8ff F, Sezer O, Lee S, Hippe E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43:1670\u20138. doi: 10.1016\/j.ejca.2007.04.022 .","journal-title":"Eur J Cancer"},{"key":"370_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","volume":"25","author":"R Walker","year":"2007","unstructured":"Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25:1121\u20138. doi: 10.1200\/JCO.2006.08.5803 .","journal-title":"J Clin Oncol"},{"key":"370_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1259\/dmfr\/74265829","volume":"40","author":"S Ghosh","year":"2011","unstructured":"Ghosh S, Wadhwa P, Kumar A, Pai KM, Seshadri S, Manohar C. Abnormal radiological features in a multiple myeloma patient: a case report and radiological review of myelomas. Dentomaxillofacial Radiol. 2011;40:513\u20138. doi: 10.1259\/dmfr\/74265829 .","journal-title":"Dentomaxillofacial Radiol"},{"key":"370_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S1297-319X(03)00152-0","volume":"71","author":"D Mulleman","year":"2004","unstructured":"Mulleman D, Gaxatte C, Guillerm G, Leroy X, Cotten A, Duquesnoy B, et al. Multiple myeloma presenting with widespread osteosclerotic lesions. Joint Bone Spine. 2004;71:79\u201383. doi: 10.1016\/S1297-319X(03)00152-0 .","journal-title":"Joint Bone Spine"},{"key":"370_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/108451","volume":"2015","author":"G Mori","year":"2015","unstructured":"Mori G, D\u2019Amelio P, Faccio R, Brunetti G. Bone-immune cell crosstalk: bone diseases. J Immunol Res. 2015;2015:1\u201311. doi: 10.1155\/2015\/108451 .","journal-title":"J Immunol Res"},{"key":"370_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Roodman","year":"2008","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2008;23:435\u201341. doi: 10.1038\/leu.2008.336 .","journal-title":"Leukemia"},{"key":"370_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.bone.2016.08.006","volume":"93","author":"J Dotterweich","year":"2016","unstructured":"Dotterweich J, Schlegelmilch K, Keller A, Geyer B, Schneider D, Zeck S, et al. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells\u2014implications for myeloma bone disease. Bone. 2016;93:155\u201366. doi: 10.1016\/j.bone.2016.08.006 .","journal-title":"Bone"},{"key":"370_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2141.2002.03417.x","volume":"117","author":"S Roux","year":"2002","unstructured":"Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand J-P, et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol. 2002;117:86\u201392. doi: 10.1046\/j.1365-2141.2002.03417.x .","journal-title":"Br J Haematol"},{"key":"370_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1158\/0008-5472.CAN-12-2280","volume":"73","author":"BJ Schmiedel","year":"2013","unstructured":"Schmiedel BJ, Scheible CA, Nuebling T, Kopp HG, Wirths S, Azuma M, et al. RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Res. 2013;73:683\u201394. doi: 10.1158\/0008-5472.CAN-12-2280 .","journal-title":"Cancer Res"},{"key":"370_CR22","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","volume":"101","author":"O Sezer","year":"2002","unstructured":"Sezer O, Heider U, Zavrski I, Kuhne C, Hofbauer L. RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 2002;101:2094\u20138. doi: 10.1182\/blood-2002-09-2684 .","journal-title":"Blood"},{"key":"370_CR23","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood-2004-02-0474","volume":"104","author":"S Colucci","year":"2004","unstructured":"Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG\/TRAIL interaction. Blood. 2004;104:3722\u201330. doi: 10.1182\/blood-2004-02-0474 .","journal-title":"Blood"},{"key":"370_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/289458","volume":"2013","author":"A Oranger","year":"2013","unstructured":"Oranger A, Carbone C, Izzo M, Grano M. Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol. 2013;2013:1\u201311. doi: 10.1155\/2013\/289458 .","journal-title":"Clin Dev Immunol"},{"key":"370_CR25","doi-asserted-by":"publisher","first-page":"10393","DOI":"10.18632\/oncotarget.2084","volume":"5","author":"M Colombo","year":"2014","unstructured":"Colombo M, Th\u00fcmmler K, Mirandola L, Garavelli S, Todoerti K, Apicella L, et al. Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget. 2014;5:10393\u2013406. doi: 10.18632\/oncotarget.2084 .","journal-title":"Oncotarget"},{"key":"370_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jbmr.2022","volume":"29","author":"P Cafforio","year":"2013","unstructured":"Cafforio P, Savonarola A, Stucci S, De Matteo M, Tucci M, Brunetti AE, et al. PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression. J Bone Miner Res. 2013;29:55\u201366. doi: 10.1002\/jbmr.2022 .","journal-title":"J Bone Miner Res"},{"key":"370_CR27","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.3324\/haematol.2015.124511","volume":"100","author":"M Westhrin","year":"2015","unstructured":"Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, et al. Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. Haematologica. 2015;100:e511\u20134. doi: 10.3324\/haematol.2015.124511 .","journal-title":"Haematologica"},{"key":"370_CR28","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1038\/leu.2008.216","volume":"22","author":"I Breitkreutz","year":"2008","unstructured":"Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008;22:1973. doi: 10.1038\/leu.2008.216 .","journal-title":"Leukemia"},{"key":"370_CR29","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","volume":"107","author":"G Anderson","year":"2006","unstructured":"Anderson G, Gries M, Kurihara N. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107:3098\u2013105. doi: 10.1182\/blood-2005-08-3450 .","journal-title":"Blood"},{"key":"370_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/jcb.10503","volume":"89","author":"A Gingery","year":"2003","unstructured":"Gingery A, Bradley E, Shaw A, Oursler MJ. Phosphatidylinositol 3-kinase coordinately activates the MEK\/ERK and AKT\/NF\u03baB pathways to maintain osteoclast survival. J Cell Biochem. 2003;89:165\u201379. doi: 10.1002\/jcb.10503 .","journal-title":"J Cell Biochem"},{"key":"370_CR31","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/sj.leu.2403269","volume":"18","author":"N Giuliani","year":"2004","unstructured":"Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia. 2004;18:628\u201335. doi: 10.1038\/sj.leu.2403269 .","journal-title":"Leukemia"},{"key":"370_CR32","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1074\/jbc.M106339200","volume":"277","author":"L Gilbert","year":"2002","unstructured":"Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1\/AML3\/Pebp2 A) Is inhibited by tumor necrosis factor. J Biol Chem. 2002;277:2695\u2013701. doi: 10.1074\/jbc.M106339200 .","journal-title":"J Biol Chem"},{"key":"370_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/172458","volume":"2015","author":"F Accardi","year":"2015","unstructured":"Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N. Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling. Biomed Res Int. 2015;2015:1\u201313. doi: 10.1155\/2015\/172458 .","journal-title":"Biomed Res Int"},{"key":"370_CR34","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","volume":"118","author":"S D\u2019Souza","year":"2011","unstructured":"D\u2019Souza S, del Prete D, Jin S, Sun Q, Huston AJ, Kostov FE, et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood. 2011;118:6871\u201380. doi: 10.1182\/blood-2011-04-346775 .","journal-title":"Blood"},{"key":"370_CR35","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","volume":"106","author":"N Giuliani","year":"2005","unstructured":"Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005;106:2472\u201383. doi: 10.1182\/blood-2004-12-4986 .","journal-title":"Blood"},{"key":"370_CR36","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2008-07-170464","volume":"113","author":"AC Sprynski","year":"2009","unstructured":"Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD, Barlogie B, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113:4614\u201326. doi: 10.1182\/blood-2008-07-170464 .","journal-title":"Blood"},{"key":"370_CR37","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/leu.2011.43","volume":"25","author":"S Vallet","year":"2011","unstructured":"Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P, et al. A novel role for CCL3 (MIP-1\u03b1) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia. 2011;25:1174\u201381. doi: 10.1038\/leu.2011.43 .","journal-title":"Leukemia"},{"key":"370_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bjh.13790","volume":"172","author":"D Kassen","year":"2015","unstructured":"Kassen D, Lath D, Lach A, Evans H, Chantry A, Rabin N, et al. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. Br J Haematol. 2015;172:64\u201379. doi: 10.1111\/bjh.13790 .","journal-title":"Br J Haematol"},{"key":"370_CR39","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/sj.onc.1206239","volume":"22","author":"Y-W Qiang","year":"2003","unstructured":"Qiang Y-W, Endo Y, Rubin JS, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene. 2003;22:1536\u201345. doi: 10.1038\/sj.onc.1206239 .","journal-title":"Oncogene"},{"key":"370_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.22","volume":"1","author":"S Colucci","year":"2011","unstructured":"Colucci S, Brunetti G, Oranger A, Mori G, Sardone F, Specchia G, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011;1, e27. doi: 10.1038\/bcj.2011.22 .","journal-title":"Blood Cancer J"},{"key":"370_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/157496","volume":"2012","author":"S Manier","year":"2012","unstructured":"Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:1\u20135. doi: 10.1155\/2012\/157496 .","journal-title":"J Biomed Biotechnol"},{"key":"370_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/erm.11.44","volume":"11","author":"SY Kristinsson","year":"2011","unstructured":"Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O. Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn. 2011;11:593\u2013603. doi: 10.1586\/erm.11.44 .","journal-title":"Expert Rev Mol Diagn"},{"key":"370_CR43","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125:3069\u201375. doi: 10.1182\/blood-2014-09-568899 .","journal-title":"Blood"},{"key":"370_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00256-008-0607-4","volume":"38","author":"TG Gleeson","year":"2008","unstructured":"Gleeson TG, Moriarty J, Shortt CP, Gleeson JP, Fitzpatrick P, Byrne B, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol. 2008;38:225\u201336. doi: 10.1007\/s00256-008-0607-4 .","journal-title":"Skeletal Radiol"},{"key":"370_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00259-005-0004-3","volume":"33","author":"C Nanni","year":"2006","unstructured":"Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33:525\u201331. doi: 10.1007\/s00259-005-0004-3 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"370_CR46","unstructured":"Nanni C, Rubello D, Zamagni E, Castellucci P, Ambrosini V, Montini G, Cavo M, Lodi F, Pettinato C, Grassetto G, Franchi R, Gross MD, Fanti S. 18F-FDG PET\/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22(4):513\u20137."},{"key":"370_CR47","series-title":"ASCO Educational Book","first-page":"1","volume-title":"Updated diagnostic criteria and staging system for multiple myeloma","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma, ASCO Educational Book. 2016. p. 1\u20136."},{"key":"370_CR48","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348. doi: 10.1016\/S1470-2045(14)70442-5 .","journal-title":"Lancet Oncol"},{"key":"370_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1517\/14712598.2015.978853","volume":"15","author":"YM Papamerkouriou","year":"2014","unstructured":"Papamerkouriou YM, Kenanidis E, Gamie Z, Papavasiliou K, Kostakos T, Potoupnis M, et al. Treatment of multiple myeloma bone disease: experimental and clinical data. Expert Opin Biol Ther. 2014;15:213\u201330. doi: 10.1517\/14712598.2015.978853 .","journal-title":"Expert Opin Biol Ther"},{"key":"370_CR50","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376. doi: 10.1182\/blood-2009-03-213280 .","journal-title":"Blood"},{"key":"370_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-014-0308-3","volume":"15","author":"F Dammacco","year":"2014","unstructured":"Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. 18F-FDG PET\/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2014;15:1\u201318. doi: 10.1007\/s10238-014-0308-3 .","journal-title":"Clin Exp Med"},{"key":"370_CR52","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11899-016-0308-3","volume":"11","author":"T Nishihori","year":"2016","unstructured":"Nishihori T, Song J, Shain KH. Minimal residual disease assessment in the context of multiple myeloma treatment. Curr Hematol Malig Rep. 2016;11:118\u201326. doi: 10.1007\/s11899-016-0308-3 .","journal-title":"Curr Hematol Malig Rep"},{"key":"370_CR53","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2141.2006.06489.x","volume":"136","author":"A Mele","year":"2007","unstructured":"Mele A, Offidani M, Visani G, Marconi M, Cambioli F, Nonni M, et al. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. Br J Haematol. 2007;136:729\u201335. doi: 10.1111\/j.1365-2141.2006.06489.x .","journal-title":"Br J Haematol"},{"key":"370_CR54","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/leu.2010.173","volume":"24","author":"E Terpos","year":"2010","unstructured":"Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010;24:1700\u201312. doi: 10.1038\/leu.2010.173 .","journal-title":"Leukemia"},{"key":"370_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.13928","volume":"173","author":"KR Ting","year":"2016","unstructured":"Ting KR, Brady JJ, Hameed A, Le G, Meiller J, Verburgh E, et al. Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br J Haematol. 2016;173:82\u20138. doi: 10.1111\/bjh.13928 .","journal-title":"Br J Haematol"},{"key":"370_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12018-013-9143-4","volume":"11","author":"N Giuliani","year":"2013","unstructured":"Giuliani N, Dalla Palma B, Bolzoni M. Bisphosphonates in multiple myeloma: preclinical and clinical data. Clinic Rev Bone Miner Metab. 2013;11:113\u201321. doi: 10.1007\/s12018-013-9143-4 .","journal-title":"Clinic Rev Bone Miner Metab"},{"key":"370_CR57","doi-asserted-by":"publisher","unstructured":"Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. 2012. doi: 10.1002\/14651858.CD003188.pub3","DOI":"10.1002\/14651858.CD003188.pub3"},{"key":"370_CR58","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long\u2010term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 2003;98:1735\u201344. doi: 10.1002\/cncr.11701 .","journal-title":"Cancer"},{"key":"370_CR59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases. JAMA. 2017;317:48. doi: 10.1001\/jama.2016.19425 .","journal-title":"JAMA"},{"key":"370_CR60","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","volume":"19","author":"GJ Morgan","year":"2013","unstructured":"Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, et al. Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013;19:6030\u20138. doi: 10.1158\/1078-0432.CCR-12-3211 .","journal-title":"Clin Cancer Res"},{"key":"370_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","volume":"62","author":"R Weitzman","year":"2007","unstructured":"Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006. Crit Rev Oncol Hematol. 2007;62:148\u201352. doi: 10.1016\/j.critrevonc.2006.12.005 .","journal-title":"Crit Rev Oncol Hematol"},{"key":"370_CR62","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","volume":"12","author":"GS Markowitz","year":"2001","unstructured":"Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"370_CR63","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s12032-010-9628-7","volume":"28","author":"MAGJ Dam ten","year":"2010","unstructured":"Dam ten MAGJ, Hilbrands LB, Wetzels JFM. Nephrotic syndrome induced by pamidronate. Med Oncol. 2010;28:1196\u2013200. doi: 10.1007\/s12032-010-9628-7 .","journal-title":"Med Oncol"},{"key":"370_CR64","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125\u201332. doi: 10.1200\/JCO.2010.31.3304 .","journal-title":"J Clin Oncol"},{"key":"370_CR65","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1200\/JCO.2010.32.5449","volume":"29","author":"E Terpos","year":"2011","unstructured":"Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol. 2011;29:1907\u201315. doi: 10.1200\/JCO.2010.32.5449 .","journal-title":"J Clin Oncol"},{"key":"370_CR66","doi-asserted-by":"crossref","unstructured":"Raje N, Santo L. New Clinical and Research Directions in Myeloma-Related Bone Disease. Hematologist. 2015;12.","DOI":"10.1182\/hem.V12.5.4355"},{"key":"370_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","volume":"131","author":"M Zangari","year":"2005","unstructured":"Zangari M, Esseltine D, Lee C-K, Barlogie B, Elice F, Burns MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71\u20133. doi: 10.1111\/j.1365-2141.2005.05733.x .","journal-title":"Br J Haematol"},{"key":"370_CR68","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","volume":"77","author":"U Heider","year":"2006","unstructured":"Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz C-O, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006;77:233\u20138. doi: 10.1111\/j.1600-0609.2006.00692.x .","journal-title":"Eur J Haematol"},{"key":"370_CR69","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","volume":"110","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007;110:334\u20138. doi: 10.1182\/blood-2006-11-059188 .","journal-title":"Blood"},{"key":"370_CR70","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","volume":"135","author":"E Terpos","year":"2006","unstructured":"Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135:688\u201392. doi: 10.1111\/j.1365-2141.2006.06356.x .","journal-title":"Br J Haematol"},{"key":"370_CR71","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/leu.2012.183","volume":"27","author":"MA Hurchla","year":"2012","unstructured":"Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2012;27:430\u201340. doi: 10.1038\/leu.2012.183 .","journal-title":"Leukemia"},{"key":"370_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074191","volume":"8","author":"B Hu","year":"2013","unstructured":"Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, et al. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS ONE. 2013;8, e74191. doi: 10.1371\/journal.pone.0074191 .","journal-title":"PLoS ONE"},{"key":"370_CR73","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1600-0609.2011.01602.x","volume":"86","author":"M Zangari","year":"2011","unstructured":"Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011;86:484\u20137. doi: 10.1111\/j.1600-0609.2011.01602.x .","journal-title":"Eur J Haematol"},{"key":"370_CR74","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/10428194.2012.728597","volume":"54","author":"YX Zhu","year":"2012","unstructured":"Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2012;54:683\u20137. doi: 10.3109\/10428194.2012.728597 .","journal-title":"Leuk Lymphoma"},{"key":"370_CR75","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/leu.2008.174","volume":"22","author":"I Breitkreutz","year":"2008","unstructured":"Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008;22:1925\u201332. doi: 10.1038\/leu.2008.174 .","journal-title":"Leukemia"},{"key":"370_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.38","volume":"3","author":"AA Chanan-Khan","year":"2013","unstructured":"Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3, e143. doi: 10.1038\/bcj.2013.38 .","journal-title":"Blood Cancer J"},{"key":"370_CR77","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1111\/bph.12742","volume":"171","author":"SL Webb","year":"2014","unstructured":"Webb SL, Edwards CM. Novel therapeutic targets in myeloma bone disease. Br J Pharmacol. 2014;171:3765\u201376. doi: 10.1111\/bph.12742 .","journal-title":"Br J Pharmacol"},{"key":"370_CR78","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.33.1.129","author":"S Munemasa","year":"2008","unstructured":"Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol. 2008. doi: 10.3892\/ijo.33.1.129 .","journal-title":"Int J Oncol"},{"key":"370_CR79","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00264-010-1127-0","volume":"35","author":"S Utzschneider","year":"2010","unstructured":"Utzschneider S, Schmidt H, Weber P, Schmidt GP, Jansson V, D\u00fcrr HR. Surgical therapy of skeletal complications in multiple myeloma. Int Orthop. 2010;35:1209\u201313. doi: 10.1007\/s00264-010-1127-0 .","journal-title":"Int Orthop"},{"key":"370_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/000164701753759546","volume":"72","author":"R Wedin","year":"2001","unstructured":"Wedin R. Surgical treatment for pathologic fracture. Acta Orthop. 2001;72:1\u201329. doi: 10.1080\/000164701753759546 .","journal-title":"Acta Orthop"},{"key":"370_CR81","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fonc.2015.00040","volume":"5","author":"G Talamo","year":"2015","unstructured":"Talamo G, Dimaio C, Abbi KKS, Pandey MK, Malysz J, Creer MH, et al. Current role of radiation therapy for multiple myeloma. Front Oncol. 2015;5:71. doi: 10.3389\/fonc.2015.00040 .","journal-title":"Front Oncol"},{"key":"370_CR82","unstructured":"Ontario Health Technology Assessment Series. Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: a systematic review. 2016;16(11):1\u2013202."},{"key":"370_CR83","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371\u20139. doi: 10.1182\/blood-2008-11-191577 .","journal-title":"Blood"},{"key":"370_CR84","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bjh.13056","volume":"167","author":"SP Iyer","year":"2014","unstructured":"Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, et al. A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014;167:366\u201375. doi: 10.1111\/bjh.13056 .","journal-title":"Br J Haematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0370-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0370-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0370-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T21:01:05Z","timestamp":1658696465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0370-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0370-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,27]]}}}